drugset / Trial / NCT03776968

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

NCT03776968

Phase 1 Completed 47 enrolled Hinova Pharmaceuticals Inc.
NaSequentialOpen-labelTreatment

Summary

This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on its pharmacokinetics in healthy Chinese adults. The study primary objective is to evaluate the HC-1119 pharmacokinetic characteristics and the effect of food on its pharmacokinetics in healthy Chinese males, subsequent to a single oral administration of HC-1119 with different doses in healthy Chinese males.

Timeline

Start
2017-10-24
Primary completion
2018-01-15
Completion
2018-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HC-1119 Unknown 40 mg Oral
Subject HC-1119 Unknown 80 mg Oral
Subject HC-1119 Unknown 160 mg Oral